ReviewCureus2025
Efficacy of High-Dose Atorvastatin Loading in Patients With ST-Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention: A Systematic Review of Randomized Controlled Trials.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of loading dose atorvastatin on postoperative cardiovascular events in elderly patients with acute myocardial infarction undergoing percutaneous coronary intervention.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ST-segment elevation myocardial infarction (STEMI) remains a leading cause of cardiovascular mortality despite advances in primary percutaneous coronary intervention (PCI) techniques. High-dose statin loading has emerged as a potential cardioprotective strategy to optimize acute outcomes through pleiotropic effects beyond lipid reduction. This systematic review synthesizes evidence from randomized controlled trials examining the efficacy and safety of high-dose atorvastatin loading in STEMI patients undergoing primary PCI. A comprehensive literature search was conducted across major databases, including PubMed, Embase, Cochrane Library, and Scopus, from inception to May 2024. Five randomized controlled trials involving 559 patients met the inclusion criteria, comparing 80 mg atorvastatin loading with standard or no loading strategies. The evidence demonstrates significant benefits in reducing the no-reflow phenomenon and significant relative risk reduction. High-dose atorvastatin loading consistently reduced inflammatory markers, including high-sensitivity C-reactive protein and interleukin-6, while improving endothelial function parameters. Angiographic outcomes showed improvements in myocardial blush grade and corrected TIMI frame count. However, translation to hard clinical endpoints such as major adverse cardiovascular events showed inconsistent results across studies. The safety profile was reassuring, with no significant increases in hepatotoxicity, myopathy, or other statin-related adverse events. Despite promising mechanistic benefits, the heterogeneity in study designs, small sample sizes, and short follow-up periods limits definitive conclusions regarding optimal dosing strategies and patient selection criteria. Future large-scale trials with standardized protocols and long-term follow-up are needed to establish the clinical utility of high-dose atorvastatin loading in STEMI patients undergoing primary PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.